A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

Palbociclib is a CDK4/6 inhibitor that received FDA approval for treatment of hormone receptor positive (HR+) HER2 negative (HER2neg) advanced breast cancer. To better personalize patients treatment it is critical to identify subgroups that would mostly benefit from it. We hypothesize that complex a...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Oncotarget
المؤلفون الرئيسيون: Malorni, Luca, Piazza, Silvano, Ciani, Yari, Guarducci, Cristina, Bonechi, Martina, Biagioni, Chiara, Hart, Christopher D., Verardo, Roberto, Leo, Angelo Di, Migliaccio, Ilenia
التنسيق: Artigo
اللغة:Inglês
منشور في: Impact Journals LLC 2016
الموضوعات:
Research Paper
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356535/
https://ncbi.nlm.nih.gov/pubmed/27634906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12010
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة